Literature DB >> 11096006

Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus.

S Harbarth1, N Liassine, S Dharan, P Herrault, R Auckenthaler, D Pittet.   

Abstract

We determined risk factors associated with persistent carriage of methicillin-resistant Staphylococcus aureus (MRSA) among 102 patients enrolled in a double-blind, placebo-controlled trial of nasally administered mupirocin ointment. MRSA decolonization was unsuccessful in 77 (79%) of 98 patients who met the criteria for evaluation. By univariate analysis, 4 variables were found to be associated with persistent MRSA colonization (P < .1 for all 4): absence of mupirocin treatment, previous fluoroquinolone therapy, > or = 2 MRSA-positive body sites, and low-level mupirocin resistance. After multivariable Cox proportional hazards modeling, the presence of > or = 2 positive body sites (adjusted hazard ratio [AHR], 1.7; 95% confidence interval [CI], 1.0-2.9) and previous receipt of a fluoroquinolone (AHR, 1.8; 95% CI, 1.0-3.3) were independently associated with MRSA persistence, whereas nasal mupirocin tended to confer protection (AHR, 0.6; 95% CI, 0.4-1.0). Low-level mupirocin resistance was observed in 9 genotypically different MRSA strains and was not independently associated with chronic MRSA carriage (AHR, 1.5; 95% CI, 0.9-2.5). Our findings suggest that multisite MRSA carriage and previous receipt of a fluoroquinolone are independent risk factors for persistent MRSA colonization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11096006     DOI: 10.1086/317484

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  51 in total

1.  [Methicillin-resistant Staphylococcus aureus--diagnosis and therapy].

Authors:  J Wüllenweber; M Herrmann
Journal:  HNO       Date:  2003-05-10       Impact factor: 1.284

2.  Persistent colonization and the spread of antibiotic resistance in nosocomial pathogens: resistance is a regional problem.

Authors:  David L Smith; Jonathan Dushoff; Eli N Perencevich; Anthony D Harris; Simon A Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-25       Impact factor: 11.205

3.  Successful treatment for carriage of methicillin-resistant Staphylococcus aureus and importance of follow-up.

Authors:  F P N Mollema; J A Severin; J L Nouwen; A Ott; H A Verbrugh; M C Vos
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

4.  Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus.

Authors:  John A Bosso; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

Review 5.  Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

Authors:  L B Rice
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

Review 6.  [The value of clinical infectology].

Authors:  M Battegay; U Flückiger
Journal:  Internist (Berl)       Date:  2005-06       Impact factor: 0.743

7.  Community-associated methicillin-resistant Staphylococcus aureus colonization burden in HIV-infected patients.

Authors:  Kyle J Popovich; Bala Hota; Alla Aroutcheva; Lisa Kurien; Janki Patel; Rosie Lyles-Banks; Amanda E Grasso; Andrej Spec; Kathleen G Beavis; Mary K Hayden; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2013-01-16       Impact factor: 9.079

8.  Nasal Carriage of Staphylococcus aureus As a Risk Factor for Skin and Soft Tissue Infections.

Authors:  J. John Weems; Luna B. Beck
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

9.  Combined topical and oral antimicrobial therapy for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization in hospitalized patients.

Authors:  Scott K Fung; Marie Louie; Andrew E Simor
Journal:  Can J Infect Dis       Date:  2002-09

10.  Long-term persistence of MRSA in re-admitted patients.

Authors:  F Mattner; F Biertz; S Ziesing; P Gastmeier; I F Chaberny
Journal:  Infection       Date:  2010-07-03       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.